Sickle Cell Disease Clinical Trial Pipeline Analysis: 55+ Key Companies Shaping the Future of Sickle Cell Disease Therapeutics | DelveInsight

DelveInsight's Sickle Cell Disease Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Sickle Cell Disease therapies in various stages of clinical development. The report provides insights into 55+ companies and 60+ drugs in the Sickle Cell Disease competitive landscape, covering therapeutic assessments by product type, stage, route of administration, and molecule type, as well as inactive pipeline products.

Key takeaways from the Sickle Cell Disease Clinical Trial Landscape Report

• DelveInsight's Sickle Cell Disease pipeline report depicts a robust space with 55+ companies working to develop 60+ pipeline therapies for Sickle Cell Disease treatment.
• Key Sickle Cell Disease companies such as Pfizer, Editas Medicine, Roche, Quercis Pharma, Graphite Bio, Beam Therapeutics Inc., GlaxoSmithKline, Agios Pharmaceuticals, BRL Medicine, Oryzon Genomics, CorrectSequence Therapeutics, GluBio Therapeutics, and Base Therapeutics.
• Promising Sickle Cell Disease pipeline therapies in various stages of development include Inclacumab, Renizgamglogene autogedtemcel, RG 6107, BEAM-101, BRL 101, and others.

Request a sample and discover the recent advances in Sickle Cell Disease treatment drugs https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Sickle Cell Disease?

Sickle Cell Disease (SCD) is a group of inherited conditions that affect red blood cells, with sickle cell anemia being the most serious type. Sickle cells are destroyed rapidly in people with the disease, causing anemia. The sickle cells can also block blood flow through vessels, resulting in pain episodes, acute chest syndrome, stroke, and damage to organs including the spleen, kidneys, and liver.
Common symptoms associated with Sickle Cell Disease include anemia, joint pain, acute chest syndrome, swelling of the hands and feet, stroke, jaundice, priapism, dizziness, fatigue, low oxygen levels, and malaise.
Sickle Cell Disease affects hemoglobin, the molecule in red blood cells responsible for delivering oxygen to cells throughout the body. When oxygen levels are insufficient, sickle hemoglobin becomes less soluble and promotes polymer formation, increasing blood viscosity and contributing to the formation of sickled red blood cells.
Sickle Cell Disease is inherited in an autosomal recessive pattern. Diagnosis can be performed through blood testing and is routinely included in newborn screening. Treatment may include lifestyle measures, medical screening, and interventions designed to prevent complications. Existing treatments include hydroxyurea, L-glutamine, voxelotor, and crizanlizumab, while several other therapies continue to undergo clinical development.

Emerging Sickle Cell Disease Drug Profiles

Inclacumab: Pfizer
Inclacumab is a fully human IgG4 anti-P-selectin monoclonal antibody being developed to reduce vaso-occlusive crises (VOCs) in patients with Sickle Cell Disease. P-selectin is a protein involved in cell adhesion and represents a clinically validated target for reducing pain associated with VOCs.
Inclacumab was originally developed by Global Blood Therapeutics, which was acquired by Pfizer. The drug is currently in the Phase III stage of development for the treatment of patients with Sickle Cell Disease.

Renizgamglogene autogedtemcel: Editas Medicine
Renizgamglogene autogedtemcel (reni-cel), formerly known as EDIT-301, is an experimental gene-editing medicine being investigated for severe Sickle Cell Disease and transfusion-dependent beta thalassemia. It consists of patient-derived CD34+ hematopoietic stem and progenitor cells edited at the gamma-globin gene (HBG1 and HBG2) promoters using AsCas12a.
The edited cells are designed to increase fetal hemoglobin production, with the potential to provide a one-time and durable treatment benefit for patients with severe Sickle Cell Disease. The drug has completed Phase III clinical development for patients with Sickle Cell Disease.

RG 6107: Roche
RG 6107, also known as SKY59, is a recycling antibody discovered by Chugai that inhibits the complement component C5. It is designed to inhibit the cleavage of C5 into C5a and C5b, thereby suppressing complement activation.
The antibody uses proprietary engineering technologies intended to extend its half-life and is being developed for subcutaneous self-injection. Currently, the drug is in the Phase II stage of development for the treatment of patients with Sickle Cell Disease.

Learn more about the novel and emerging Sickle Cell Disease pipeline therapies https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Sickle Cell Disease Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key Sickle Cell Disease Companies: Pfizer, Editas Medicine, Roche, Quercis Pharma, Graphite Bio, Beam Therapeutics Inc., GlaxoSmithKline, Agios Pharmaceuticals, BRL Medicine, Oryzon Genomics, CorrectSequence Therapeutics, GluBio Therapeutics, Base Therapeutics
• Key Sickle Cell Disease Pipeline Therapies: Inclacumab, Renizgamglogene autogedtemcel, RG 6107, BEAM-101, BRL 101, and others.

Dive deep into rich insights for new drugs for Sickle Cell Disease treatment, visit https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Sickle Cell Disease Pipeline Report Introduction
2. Sickle Cell Disease Pipeline Report Executive Summary
3. Sickle Cell Disease: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Sickle Cell Disease Pipeline Therapeutics
6. Sickle Cell Disease Pipeline: Late Stage Products (Phase III)
7. Sickle Cell Disease Pipeline: Mid Stage Products (Phase II)
8. Sickle Cell Disease Pipeline: Early Stage Products (Phase I/II)
9. Sickle Cell Disease Pipeline: Preclinical and Discovery Stage Products
10. Sickle Cell Disease Pipeline Therapeutics Assessment
11. Inactive Products in the Sickle Cell Disease Pipeline
12. Key Companies
13. Key Products in the Sickle Cell Disease Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Sickle Cell Disease pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe.

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.